GE Healthcare Ltd. et al. vs. The Johns Hopkins University et al.

Explore the PTAB proceeding PGR2025-00059 filed by GE Healthcare Ltd. et al. on 2025-07-14. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

PGR2025-00059

Filing Date

2025-07-14

Accorded Filing Date

2025-07-14

Institution Decision Date

2026-01-14

Last Modified Date

2026-10-14

Proceeding Type

PGR

Termination Date

2026-10-14

Trial Status

Terminated-Settled

Parties & Counsel

Petitioner

GE Healthcare Ltd. et al.

Represented By

Kushan, Jeffreyet al

Patent Owner / Respondent

The Johns Hopkins University et al.

Represented By

Ellison, Eldoraet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 18585905

Respondent Patent Number 12115233

External Links

Espacenet

Google Patents

Respondent Inventor Xing Yang et al

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

33 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name The Johns Hopkins University - c/o Casimir Jones

Customer Number 101943

Address 2275 Deming Way, Suite 310, Middleton, WI, 53562, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
38978	Lisa Mueller	312-222-0800
42363	Mary Ann Brow	608-662-1277
42395	David Casimir	608-662-1277
44174	John Jones	608-662-1277
45439	Jason Bond	608-662-1277
47371	Rick Abegglen	608-237-7288
47391	Tanya Arenson	608-662-1277
50210	Thomas Haas	202-659-6659
52926	Tristan Fuierer	608-662-1277
52933	Guido Galvez	410-502-9593
55210	Robert Goetz	608-662-1277
58126	Jeffrey Childers	919-724-8699
59520	Linda Hutchison	410-978-7287
59850	Tyler Sisk	608-662-1277
63215	Louisa Salomon	571-271-7116
63532	Laura Mitchell	410-516-4969
63749	Qi Zhuo	973-245-7747
65033	Kirk Hogan	608-662-1277
65455	Anne Reynolds	608-662-1277
65746	Alevtina Zhelonkina	410-516-7789
65881	Andrew Wichmann	202-787-5532
65903	David Staple	608-662-1277
67792	Peter Schlueter	608-257-3501
71476	Thomas Isenbarger	608-662-1277
71554	Peter Sheppard	443-963-2909
73951	Brian Bradley	608-662-1277
74648	Sempian Sooriakumar	585-469-5508
77414	Rikki Hullinger	508-523-6096
78227	Kelly Barton	608-662-1277
78563	Vincent Carbone	410-308-8897
78578	Anthony Sedivy	440-590-0457
80602	Thomas Lyneis	414-287-9646
82885	Bradley Loren	312-775-8009

Proceeding Documents

177

Termination Decision: Post-DI Settlement TERMINATE

2026-10-14 FILING PARTY: BOARD

Download

Joint Motion to Keep Business Confidential and Separate Separate MOTION

2026-10-01 FILING PARTY: PETITIONER

Download

Joint Motion to Terminate MOTION

2026-10-01 FILING PARTY: PETITIONER

Download

ORDER Setting Oral Argument 37 C.F.R. § 42.70 ORDER

2026-09-17 FILING PARTY: BOARD

Download

Patent Owner's Request for Oral Argument OTHER

2026-09-02 FILING PARTY: PATENT OWNER

Download

GE Healthcare Ltd. et al. vs. The Johns Hopkins University et al.

Proceeding Overview

Parties & Counsel

Petitioner

GE Healthcare Ltd. et al.

Represented By

Patent Owner / Respondent

The Johns Hopkins University et al.

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Termination Decision: Post-DI Settlement TERMINATE

Joint Motion to Keep Business Confidential and Separate Separate MOTION

Joint Motion to Terminate MOTION

ORDER Setting Oral Argument 37 C.F.R. § 42.70 ORDER

Patent Owner's Request for Oral Argument OTHER

Petitioner's Request for Oral Argument OTHER

Order: Granting Petitioners Motion to Seal 37 C.F.R. sec. 42.14 ORDER

Walsh et al., “Biopharmaceutical benchmarks 2022,” Nature Biotechnology, 40:1722-1760 (2022) Exhibit

Huang et al., “The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with ± 11C-YJH08 PET,” Journal of Nuclear Medicine, 62:(5) 723–731 (2020) Exhibit

BPS Bioscience Inc., FAP His-Tag Recombinant FAP 80100, https://bpsbioscience.com/fap-his-tag-recombinant-80100 Exhibit

Second Declaration of Kushan Exhibit

REDACTED Second Declaration of Dr. Brian Zeglis Exhibit

Frangioni, “In vivo near-infrared fluorescence imaging,” Current Opinion in Chemical Biology, 7:626–634 (2003) Exhibit

FDA and EMA Access Data Exhibit

Dr. VanBrocklin Annotation of XY-FAP-01 Exhibit

Fulop et al., “Prolyl Oligopeptidase: An Unusual ß-Propeller Domain Regulates Proteolysis,” Cell, 94:161–170 (1998) Exhibit

Errata to Declaration of Dr. Henry VanBrocklin Exhibit

Baker et al., “Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A1 receptor ligands,” British Journal of Pharmacology, 159:772-786 (2010) Exhibit

Su et al., “Evaluation of [18F]getfitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors,” European Journal of Nuclear Medicine and Molecular Imaging, 35:1089–1099 (2008) Exhibit

Vasdev et al., “Metabolic stability of 6,7-dialkoxy-4-(2-, 3- and 4- [18F]fluoroanilino)quinazolines, potential EGFR imaging probes,” Bioorganic & Medicinal Chemistry, 19:2959–2965 (2011) Exhibit

Transcript of the Deposition of Dr. Henry VanBrocklin, July, 29, 2026 Exhibit

Dannoon et al., “Structure—Activity Relationship of 18F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer,” Journal of Medicinal Chemistry, 59:5684–5694 (2016) Exhibit

Ganguly et al., “A high-affinity [18F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer,” Journal of Nuclear Medicine and Biology, 42:780–787 (2015) Exhibit

REDACTED Petitioner's Reply REPLYTOOPP

Biotechne R&D Systems, Recombinant Human Fibroblast Activation Protein a/FAP Catalog Number 3715-SE, https://bio-tehche.com/p/proteins-enzymes/recombinant-human-fap-protein-cf_3715-se#product-specifications Exhibit

Petitioner's Updated Exhibit List NOTICE

Arruebo et al., “Assessment of Evolution of Cancer Treatment Therapies,” Cancers, 3:3279–3330 (2011) Exhibit

PREP Tissue, The Human Protein Atlas, https://www.proteinatlas.org/ENSG00000085377-PREP/tissue Exhibit

Petitioner's Motion to Seal Petitioner's Reply to Patent Owner Response and Exhibits MOTION

Dr. VanBrocklin Annotation of XY-FAP-02 Exhibit

Notice of Joint Stipulation to Modify Due Date 2 NOTICE

Exhibit 3004 Exhibit

Order: SECOND REVISED SCHEDULING ORDER ORDER

Patent Owner's Updated Exhibit List NOTICE

EX2060 - Teleconference Transcript Exhibit

Notice of Joint Stipulation to Modify Due Date 2, 3, 5, and 6 NOTICE

Ex. 3003 Exhibit

ORDER Conduct of the Proceeding 37 C.F.R. § 42.5 ORDER

REVISED SCHEDULING ORDER ORDER

Joint Motion to Enter Modified Protective Order MOTION

Declaration of Amit Bhatla Exhibit

Notice of Intent to Designate Amit Bhatla Provisionally Recognized PTAB Attorney as Backup Counsel NOTICE

Petitioner's Updated Exhibit List NOTICE

Order: Granting Motion for Additional Discovery ORDER

Petitioner's Notice of Deposition of Henry F. VanBrocklin, Ph.D. NOTICE

Notice of Joint Stipulation to Modify Due Dates 2, 3, 5 and 6 NOTICE

Patent Owner's Opposition to Petitioner's Motion for Additional Discovery OPPOSITION

Ex. 3002 Exhibit

Petitioner's Updated Exhibit List NOTICE

Email Correspondence re: Pomper Declaration Discovery (Apr. 22, 2026 – May 4, 2026) Exhibit

Petitioner's Motion for Additional Discovery MOTION

PCT/US2022/023374 Exhibit

Order: Conduct of the Proceeding 37 C.F.R. sec. 42.5 ORDER

Ex. 3001 Exhibit

Petitioner's Objections to Evidence OTHER

EX2044 - Petri 2021 Exhibit

EX2051 - Wilbur 1992 Exhibit

EX2043 - Rablen Exhibit

EX2052 - Glaser 2008 Exhibit

EX2020 - Poplawski 2013 Exhibit

Patent Owner's Response RESPONSE

EX2029 - VanBrocklin Declaration Exhibit

EX2021 - US-633 Ia-Ik (Zeglis Annotations) Exhibit

EX2041 - Zeglis 2014 Exhibit

EX2038 - Keane 2011 Exhibit